VIDEO: EYP-1901 shows positive vision, treatment burden outcomes at 1 year
Click Here to Manage Email Alerts
CHICAGO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Carl D. Regillo, MD, FACS, of Wills Eye Hospital, shares study results from the phase 2 DAVIO 2 trial.
The trial investigated EYP-1901 (vorolanib, EyePoint Pharmaceuticals) as a treatment for wet age-related macular degeneration at 12 months following a single injection. The trial included 161 previously treated patients.
According to Regillo, the trial met its primary endpoint of noninferiority in change in best corrected visual acuity compared with aflibercept at two doses. In addition, the data showed a “tremendous reduction in treatment burden” with a “very favorable safety profile,” he said.
Collapse
Regillo C. EYP-1901 for the treatment of neovascular AMD: Phase 2 DAVIO2 end-of-study 12-month results. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.
Read more about
Click Here to Manage Email Alerts